MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma
Toxicological Sciences · 2025
DOI: 10.1093/toxsci/kfae126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, 2025. Verfasst von Xinjun Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biliary-Pancreatic Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Mad2 Proteins, Liver Neoplasms, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Guangdong Basic and Applied Basic Research Foundation, Science and Technology Program of Guangzhou.
Abstract (Originalsprache)
Mitotic arrest-deficient 2 like 1 (MAD2L1) is a component of the mitotic spindle assembly checkpoint implicated in cancer cell proliferation and tumorigenesis. The functional role of MAD2L1 in hepatocellular carcinoma (HCC) has not been adequately investigated, especially in vivo. In the current manuscript, we sought to address the function of MAD2L1 in hepatocarcinogenesis. We found that MAD2L1 expression is upregulated in human HCCs, where its expression is associated with higher aggressive tumor grade, elevated proliferative activity, and poor prognosis. In human HCC cell lines, MAD2L1 knockdown led to decreased cell growth. Moreover, RNA-seq results demonstrated that MAD2L1 silencing induces the expression of genes associated with cell cycle, DNA replication, and various cancer-related pathways, supporting the critical role of MAD2L1 during HCC growth and differentiation. In a c-MYC-induced mouse HCC model, we revealed an increased expression of Mad2l1. Furthermore, Mad2l1 CRIPSR-mediated silencing prevented c-MYC-driven mouse liver development. Altogether, our study suggests that MAD2L1 plays a crucial role in hepatocarcinogenesis, and that its suppression could be a promising therapeutic strategy for treating human HCC. MAD2L1 plays a critical role in liver cancer development, silencing MAD2L1 reduced cell growth in vitro and inhibited c-MYC-driven liver cancer development in vivo. MAD2L1 suppression might be a promising therapeutic approach for treating human liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biliary-Pancreatic Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
- Cancer Biology Program, University of Hawai'i Cancer Center, University of Hawai'i, Honolulu, HA 96813, United States.
- Institute of Pathology, University of Regensburg, Regensburg 93053, Germany.
ORCID-Profile: Xin Chen
Förderung
- NCI NIH HHS
- Guangdong Basic and Applied Basic Research Foundation
- Science and Technology Program of Guangzhou
- NIH HHS
- National Institutes of Health
Zitieren
APA
Lu, X., Zhang, Y., Xue, J., Evert, M., Calvisi, D., Chen, X., & Wang, X. (2025). MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae126
Vancouver
Lu X, Zhang Y, Xue J, Evert M, Calvisi D, Chen X, et al. MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma. Toxicological Sciences. 2025. doi:10.1093/toxsci/kfae126
BibTeX
@article{Lu2025,
author = {Lu, Xinjun and Zhang, Ya and Xue, Jiahao and Evert, Matthias and Calvisi, Diego and Chen, Xin and Wang, Xue},
title = {MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma},
journal = {Toxicological Sciences},
year = {2025},
doi = {10.1093/toxsci/kfae126}
}
EUVIMED